Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Application of cellular and tissue-based products to wounds; the loudest category in Open Payments. Main billing specialties: podiatry, wound care and vascular surgery.
Medicare fee-for-service skin substitutes & wound grafts cases in the 50 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (246 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 313 | 86,283+22%/yr | +22%/yr | 15.61.6× | 83% | 134,700 in 2030+7.7%/yr |
| Florida | 307 | 65,607+28%/yr | +28%/yr | 16.81.8× | 81% | 135,200 in 2030+13%/yr |
| Texas | 193 | 48,756+22%/yr | +22%/yr | 13.21.4× | 77% | 79,300 in 2030+8.4%/yr |
| Illinois | 83 | 23,783+12%/yr | +12%/yr | 11.51.2× | 50% | 36,600 in 2030+7.5%/yr |
| Arizona | 83 | 15,125+16%/yr | +16%/yr | 12.61.3× | 85% | 26,900 in 2030+10%/yr |
| New York | 70 | 14,481+3.3%/yr | +3.3%/yr | 4.70.5× | 45% | 20,500 in 2030+5.9%/yr |
| Georgia | 65 | 14,399+9.3%/yr | +9.3%/yr | 9.71.0× | 74% | 20,000 in 2030+5.6%/yr |
| Nevada | 52 | 12,513+43%/yr | +43%/yr | 26.22.8× | 72% | 17,600 in 2030+5.9%/yr |
| Ohio | 39 | 12,139+7.6%/yr | +7.6%/yr | 6.30.7× | 47% | 15,800 in 2030+4.5%/yr |
| New Jersey | 47 | 11,826+17%/yr | +17%/yr | 7.70.8× | 65% | 21,200 in 2030+10%/yr |
| Oklahoma | 48 | 11,719+21%/yr | +21%/yr | 16.61.7× | 72% | 19,200 in 2030+8.6%/yr |
| Indiana | 43 | 11,035+8.2%/yr | +8.2%/yr | 9.81.0× | 38% | 11,900 in 2030+1.2%/yr |
| Michigan | 37 | 10,345+8%/yr | +8%/yr | 6.50.7× | 46% | 13,300 in 2030+4.3%/yr |
| Pennsylvania | 30 | 9,758+2.6%/yr | +2.6%/yr | 4.20.4× | 75% | 13,200 in 2030+5.2%/yr |
| Tennessee | 38 | 9,735+16%/yr | +16%/yr | 8.30.9× | 69% | 15,600 in 2030+8.1%/yr |
| Virginia | 47 | 9,709+14%/yr | +14%/yr | 6.50.7× | 70% | 21,900 in 2030+14%/yr |
| South Carolina | 44 | 8,777+14%/yr | +14%/yr | 8.40.9× | 72% | 16,300 in 2030+11%/yr |
| Kansas | 36 | 8,726+10%/yr | +10%/yr | 16.11.7× | 71% | 13,300 in 2030+7.2%/yr |
| Mississippi | 39 | 8,487+28%/yr | +28%/yr | 15.31.6× | 68% | 14,900 in 2030+9.8%/yr |
| Missouri | 32 | 8,053+4.4%/yr | +4.4%/yr | 7.70.8× | 47% | 8,660 in 2030+1.2%/yr |
| Alabama | 31 | 7,567+19%/yr | +19%/yr | 9.41.0× | 82% | 11,800 in 2030+7.7%/yr |
| North Carolina | 35 | 7,475+4.4%/yr | +4.4%/yr | 4.40.5× | 66% | 10,800 in 2030+6.4%/yr |
| Washington | 21 | 7,289+5.2%/yr | +5.2%/yr | 5.90.6× | 78% | 11,800 in 2030+8.4%/yr |
| Kentucky | 24 | 7,085+18%/yr | +18%/yr | 9.21.0× | 65% | 11,400 in 2030+8.3%/yr |
| Louisiana | 33 | 6,694+10%/yr | +10%/yr | 9.41.0× | 82% | 12,700 in 2030+11%/yr |
| Colorado | 27 | 6,374+23%/yr | +23%/yr | 7.80.8× | 82% | 11,000 in 2030+9.5%/yr |
| Massachusetts | 33 | 6,154+1.6%/yr | +1.6%/yr | 4.70.5× | 36% | 6,700 in 2030+1.4%/yr |
| Utah | 18 | 5,940+21%/yr | +21%/yr | 16.21.7× | 77% | 5,190 in 2030−2.2%/yr |
| Maryland | 25 | 5,850+12%/yr | +12%/yr | 5.30.6× | 70% | 12,200 in 2030+13%/yr |
| Arkansas | 17 | 4,095+20%/yr | +20%/yr | 7.10.7× | 73% | 6,940 in 2030+9.2%/yr |
| Minnesota | 15 | 3,990+14%/yr | +14%/yr | 4.80.5× | 50% | 5,210 in 2030+4.5%/yr |
| Wisconsin | 12 | 3,903−0.1%/yr | −0.1%/yr | 3.90.4× | 25% | 4,360 in 2030+1.8%/yr |
| Oregon | 20 | 3,597+11%/yr | +11%/yr | 5.00.5× | 89% | 4,970 in 2030+5.5%/yr |
| Iowa | 5 | 3,495−1.6%/yr | −1.6%/yr | 5.70.6× | 40% | 2,680 in 2030−4.3%/yr |
| West Virginia | 12 | 3,280+21%/yr | +21%/yr | 9.31.0× | 82% | 4,240 in 2030+4.4%/yr |
| Connecticut | 15 | 3,005+7.9%/yr | +7.9%/yr | 5.30.6× | 50% | 4,060 in 2030+5.1%/yr |
| Nebraska | 10 | 2,307+4.5%/yr | +4.5%/yr | 6.60.7× | 54% | 3,570 in 2030+7.5%/yr |
| Idaho | 11 | 2,190+7.1%/yr | +7.1%/yr | 6.80.7× | 51% | 4,080 in 2030+11%/yr |
| New Mexico | 9 | 2,075+17%/yr | +17%/yr | 5.60.6× | 92% | 2,610 in 2030+3.9%/yr |
| Delaware | 5 | 1,763+16%/yr | +16%/yr | 7.80.8× | 92% | 3,650 in 2030+13%/yr |
| Montana | 9 | 1,642+11%/yr | +11%/yr | 6.70.7× | 62% | 1,670 in 2030+0.3%/yr |
| New Hampshire | 12 | 1,375+11%/yr | +11%/yr | 4.40.5× | 20% | 1,740 in 2030+4%/yr |
| South Dakota | 7 | 1,064−2.8%/yr | −2.8%/yr | 6.00.6× | 16% | 1,440 in 2030+5.1%/yr |
| District of Columbia | 4 | 1,007+12%/yr | +12%/yr | 11.61.2× | 83% | 2,200 in 2030+14%/yr |
| Rhode Island | 3 | 886−5.4%/yr | −5.4%/yr | 5.20.5× | 41% | 870 in 2030−0.4%/yr |
| Maine | 4 | 721−5.3%/yr | −5.3%/yr | 2.60.3× | 14% | 740 in 2030+0.5%/yr |
| North Dakota | 1 | 700+2.6%/yr | +2.6%/yr | 5.20.5× | 34% | 600 in 2030−2.5%/yr |
| Hawaii | 3 | 546+7.6%/yr | +7.6%/yr | 2.40.3× | 74% | 1,080 in 2030+12%/yr |
| Wyoming | 0 | 397+25%/yr | +25%/yr | 3.20.3× | 90% | 650 in 2030+8.5%/yr |
| Alaska | 1 | 290−8.4%/yr | −8.4%/yr | 2.40.2× | 29% | 500 in 2030+9.7%/yr |
Professional codes (what the surgeon bills): CPT 15271, 15273, 15275, 15277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 301 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 134 companies. The most active:
Product codes: FRO (dressing, wound, drug), KGN (wound dressing with animal-derived material(s)), MDD (device, dermal replacement), MGP (dressing, wound and burn, occlusive), MGQ (dressing, wound and burn, hydrogel w/drug and/or biologic), MGR (dressing, wound and burn, interactive). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +31 pts since 2019, to 70%.
The 10 busiest do 21% of the cases CMS names in California; 135 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Debridement & negative-pressure wound therapy | 14,239 | 3,389,687−0.3%/yr | −0.3%/yr | 3,953,800 in 2030+2.6%/yr |
| Bone graft & orthobiologics | 545 | 22,075−9.8%/yr | −9.8%/yr | 22,500 in 2030+0.3%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 40 companies reported engagement with surgeons in the covered states worth $17M in consulting, speaking, meals and travel tied to these products, about $8,064 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 37 clearances and approvals in the category, 13 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.